2012 Annual Report Our Diversified Portfolio and  Pipeline This foundation, in turn, made it possible for us to work through challenges and seize opportunities in 2012, while positioning ourselves for a successful future. Most notably, it helped us to manage  the losses of exclusivity of  Plavix  and  Avapro / Avalide . Having long known  that two of our biggest products were  going off patent in 2012 and that the  financial impact would be consider- able, we planned accordingly and  executed successfully. We strength- ened our diversified portfolio with new  products and new indications. We  achieved significant clinical advances.  And we renewed our commitment to  productivity. In the last weeks of the year, we  gained several approvals for  Eliquis ,  a new medication for the prevention  of stroke and systemic embolism for  adult patients with nonvalvular atrial  fibrillation, or NVAF. Specifically,  Eliquis  was approved in Europe, Canada, Japan and the United States. This was an important development  for patients. Atrial fibrillation is a  common heart arrhythmia that affects  millions of people worldwide. It is a  condition that significantly increases  the risk of stroke as well as the bur- den to patients who suffer a stroke.  This was also an important devel- opment for physicians.  Eliquis  is  the only anticoagulant with proven  superior risk reduction versus war- farin in the three critical outcomes  of stroke prevention, major bleeding  and all-cause death in patients with  NVAF. For nearly 60 years, warfarin  In 2012, we continued to expand our  Onglyza  franchise and delivered a  50% increase in year-over-year sales. We also acquired Amylin, a biophar- maceutical company specializing  in diabetes and other metabolic  These developments reaffirmed  Bristol-Myers Squibb’s position as  Our Research and Development team  also made progress with two potential  products – nivolumab, which is in  Phase III trials for lung, renal and skin  cancers, and elotuzumab, for multiple  myeloma. Yervoy  continued to get established  in markets throughout the world. Global sales increased 96% over the  previous year, and this breakthrough  product demonstrated an unprec- edented 5-year survival curve for  melanoma patients. Finally, this was a very positive  development for our company and  for our alliance with Pfizer, because it  further underscored the value of our  partnership and the leadership role  both companies continue to play in  providing innovative medicines for the  treatment of cardiovascular disease.  has been the standard of care for this  patient population. In light of all of these developments,  we are now able to offer three innova- tive classes of medicines to help  address the diverse needs of patients  with type 2 diabetes. This is good  news for our company and for the  patients we serve. Type 2 diabetes is a chronic, progressive disease  that is growing in prevalence across  the globe. According to the World  Health Organization (WHO), there  are an estimated 346 million people  with diabetes worldwide. By 2030,  that number is projected to double.  Consequently, there is a real need for new treatment options. “Simply stated, our BioPharma Transformation has been built on a solid foundation of realistic expectations, high aspirations and a  commitment to excellence  that runs throughout our  entire company.” Toward the end of the year, we gained  European Commission approval for  Forxiga , a once-daily oral medication  that provides a completely new option  to improve glycemic control in adult  patients with type 2 diabetes. diseases, and with it, three mar- keted products, including  Byetta and  Bydureon , and a state-of-the-art  manufacturing plant in Ohio. And very importantly, we also expanded  our 5-year-old diabetes partnership  with AstraZeneca.  Lamberto Andreotti, Chief Executive Officer Immuno-Oncology Cardiovascular Disease Diabetes 2 Bristol-Myers Squibb 